The anti-tuberculosis agents under development and the challenges ahead.

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a significant global health threat, causing 1.5 million deaths annually.
• The emergence of drug-resistant TB strains and HIV co-infection has complicated treatment and increased disease incidence.
• While first-line drugs reduced mortality, new therapeutic strategies are crucial.

Purpose of the Study:

• To review the current landscape of antitubercular drug development.
• To highlight novel drug candidates and repurposed agents in clinical and preclinical stages.
• To discuss future directions in TB pharmacotherapy.

Main Methods:

• Literature review of recent clinical trials and preclinical studies on anti-TB drug candidates.
• Analysis of compounds with novel mechanisms of action and repurposed antibiotics.
• Evaluation of approved drugs for multidrug-resistant TB (MDR-TB).

Main Results:

• Several novel antitubercular agents are in various phases of clinical development (e.g., PA-824, SQ109, AZD5847).
• Repurposed antibiotics like gatifloxacin, moxifloxacin, and linezolid are being evaluated for TB activity.
• OPC-67683 and TMC207 are recently approved for MDR-TB treatment, with numerous other compounds in development.

Conclusions:

• The pipeline for TB drug development is active, featuring diverse compounds and novel mechanisms.
• Repurposing existing antibiotics and developing new agents are key strategies against drug-resistant TB.
• Continued research and clinical evaluation are essential to combat the global TB burden.